For the Inventor, By the Inventor

Enter inventor name

Cambridge, MA, United States of America

Dasa Lipovsek

USPTO Granted Patents = 53 (Patent Applications = 17)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 28)

Average Co-Inventor Count = 3.8

ph-index = 12

Forward Citations = 710(Granted Patents)

Forward Citations (Not Self Cited) = 510(Dec 10, 2025)

Location History:

Cambridge, MA (US) (2004 - 2024)
Pepperell, MA (US) (2019 - 2024)

Company Filing History:

48 out of 3,685

Bristol-myers Squibb Compnay

Compound Therapeutics, Inc.

Bristol Meyers Squibb Company

Aktis Oncology, Inc.

Years Active: 2004-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Nectin-4 Binding Miniproteins

Modified FGF-21 Polypeptides

PD-L1 Binding Polypeptides

Fibronectin Based Scaffold Proteins

Modified Relaxin Polypeptides

Glypican-3 Binding Molecules

Serum Albumin Binding Domains

Binding Protein Selection Methods

Therapeutic Uses of Polypeptides

Imaging Techniques in Biomedicine

Protein Scaffolds for Antibody Mimics

Nucleic Acid Assembly Technologies

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427212 - Nectin-4 binding miniproteins, conjugates and uses thereof (2025-09-30),

2. 12247058 - Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof (2025-03-11),

3. 12194110 - PD-L1 binding polypeptides for imaging (2025-01-14),

4. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides (2024-09-24),

5. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides (2024-09-24),

6. 11913137 - Methods for the selection of binding proteins (2024-02-27),

7. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9 (2024-01-02),

8. 11813315 - Fibronectin based scaffold domain proteins that bind to myostatin (2023-11-14),

9. 11524992 - Glypican-3-binding fibronectin based scaffold molecules (2022-12-13),

10. 11447538 - Fibronectin based scaffold proteins (2022-09-20),

11. 11434275 - Fast-off rate serum albumin binding fibronectin type III domains (2022-09-06),

12. 11408093 - Fibronectin binding domains with reduced immunogenicity (2022-08-09),

13. 11407815 - Stabilized fibronectin based scaffold molecules (2022-08-09),

14. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof (2022-06-21),

15. 11344639 - PET imaging with PD-L1 binding polypeptides (2022-05-31),

Title: The Innovative Mind of Dasa Lipovsek: Revolutionizing Healthcare

Introduction:

Dasa Lipovsek, a visionary inventor based in Cambridge, MA, has made significant contributions to the field of healthcare with her groundbreaking patents and research. With a total of 50 patents to her name, Dasa's work has focused on developing novel therapies for a range of cardiovascular and renal conditions.

Latest Patents:

Dasa's recent patents showcase her cutting-edge approach to medical innovation. One of her latest inventions involves the use of modified relaxin polypeptides for the treatment of fibrosis, cardiovascular disease, and heart failure. These modified polypeptides have shown promise in improving patient outcomes and quality of life. Another patent highlights her methods for treating kidney failure and enhancing renal function using similar pharmacokinetic enhancers.

Career Highlights:

During her illustrious career, Dasa has been associated with renowned companies in the pharmaceutical and biotechnology sectors. She has made significant contributions to organizations like Bristol-Myers Squibb Company and Compound Therapeutics, Inc. Her expertise and leadership have been instrumental in driving innovation and pushing the boundaries of medical research.

Collaborations:

Dasa's collaborative spirit has led to fruitful partnerships with industry experts like Ray Camphausen and Jonathan Harry Davis. Together, they have worked on various projects aimed at advancing the field of healthcare and developing more effective treatment options for patients. Dasa's ability to collaborate with diverse teams underscores her commitment to fostering innovation in the scientific community.

Conclusion:

In conclusion, Dasa Lipovsek stands as a beacon of innovation in the healthcare industry. Her relentless pursuit of excellence and passion for improving patient care have resulted in groundbreaking inventions that have the potential to transform the way we approach cardiovascular and renal diseases. With a career marked by creativity and ingenuity, Dasa continues to inspire future generations of inventors and researchers in the pursuit of life-changing medical advancements.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…